PTPN11 and cancer: As of December 2023, at least ten PTPN11 inhibitors have reached Phase I/II clinical trials for the treatment of solid tumours either as monotherapies or in combination with other anti-cancer drugs, including TKIs and immune checkpoint inhibitors (Table 1).